Cancer Research Landon Prizes for Basic and Translational Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 519-523, February 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shewach, D. S.
Right arrow Articles by Daddona, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shewach, D. S.
Right arrow Articles by Daddona, P. E.

Potentiation of 2'-Deoxyguanosine Cytotoxicity by a Novel Inhibitor of Purine Nucleoside Phosphorylase, 8-Amino-9-benzylguanine1

Donna S. Shewach2, Ji-Wang Chern, Katherine E. Pillote, Leroy B. Townsend and Peter E. Daddona3

Departments of Internal Medicine [D.S.S., P.E.D.], Biological Chemistry [P.E.D.], and Medicinal Chemistry [J-W.C., K.E.P., L.B.T.], University of Michigan, Ann Arbor, Michigan 48109

We have synthesized and evaluated a series of 9-substituted analogues of 8-aminoguanine, a known inhibitor of human purine nucleoside phosphorylase (PNP) activity. The ability of these agents to inhibit PNP has been investigated. All compounds were found to act as competitive (with inosine) inhibitors of PNP, with Ki values ranging from 0.2 to 290 µM. The most potent of these analogues, 8-amino-9-benzylguanine, exhibited a Ki value that was 4-fold lower than that determined for the parent base, 8-aminoguanine. As a metabolically stable compound in human blood, 8-amino-9-benzylguanine was more effective than 8-aminoguanine at potentiating the toxicity of 2'-deoxyguanosine to MOLT-4 T-lymphoblasts in culture. 8-Amino-9-benzylguanine is the most potent base or nucleoside inhibitor of human PNP reported to date, and it is a promising lead compound in the development of more effective PNP inhibitors.

1 This investigation was supported by Public Health Service grants CA-26284 (P. E. D.) and CA-28381 (L. B. T.) awarded by the National Cancer Institute, Department of Health and Human Services, and aided by grant CH-299 (L. B. T.) from the American Cancer Society.

2 Arthritis Foundation Fellow.

3 To whom requests for reprints should be addressed, at the Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109.

Received 8/15/85. Revised 10/23/85. Accepted 10/25/85.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
L. A. Loeb, J. M. Essigmann, F. Kazazi, J. Zhang, K. D. Rose, and J. I. Mullins
Lethal mutagenesis of HIV with mutagenic nucleoside analogs
PNAS, February 16, 1999; 96(4): 1492 - 1497.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.